1. Domestic policy: April 2021, Semaglutide injection has been approved in mainland China, with the same indications as the two earliest approved indications in the US market, and has been eligible for medical insurance.

2. Application field: Semaglutide has excellent performance in the field of diabetes and weight loss, with a market scale of more than 10billion US dollars. The global total usage exceeded 500 kilograms in 23 years and is expected to increase by over 20% in 24 years.

3. Project foundation: Due to the strong correlation of the industrial chain, our company has accumulated a large amount of experience in the production and preparation of peptide drugs, and has mastered the best domestic preparation process of Semaglutide.

4. Project advantage: We have a more advantageous production process, which can compress the production cost to $90/g (the market price is $1000, the average production cost is $300-400), the price advantage is obvious. 25-26 year is expected to declare oral preparations, the market demand will be enlarged by 20 to 30 times.

5. Project value: API, the first phase of production, can produce 20KG/ year, the second year can achieve the output of more than 40KG/ year, according to the current price estimate, the output value can reach $40million dollars per year. After the approval of the preparation factory, the annual output value of a single product will exceed $150 million dollars per year.